Abstract
Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B-cell receptor pathway, is an effective therapeutic agent for B-cell lymphomas. As the......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
